Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer

Lee Resta,Sabine Ermisch,Connie Collins,Steven Nicol,Deborah K. Armstrong,Ting Wang,Zhe Zhang,Donald Thornton,Michael A. Carducci

Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer

2008

Lee Resta
Sabine Ermisch
Connie Collins
Steven Nicol
Deborah K. Armstrong
Ting Wang
Zhe Zhang
Donald Thornton
Michael A. Carducci

3529 Background: ENZ is an oral kinase inhibitor that suppresses tumor growth through PKC and PI-3 kinase/AKT. BV is a monoclonal antibody that binds VEGF and inhibits angiogenesis. Since ENZ and B...

Keywords:

Bevacizumab
Enzastaurin
Cancer
Physical therapy
Medicine
Protein kinase B
Angiogenesis
Pathology
Kinase
Cancer research
Protein kinase C
Monoclonal antibody
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations